Impact Of Inclisiran on Major Adverse Cardiovascular Events in Participants with Established Cardiovascular Disease (VICTORION-2 PREVENT)

Brief description of study

The purpose of this research study is to determine if the study treatment, an FDA approved drug known to be safe and effective in lowering bad cholesterol called inclisiran, taken in addition to a statin medication used to treat people with established cardiovascular disease, can safely and effectively lower the risk of cardiovascular events in the future (such as or including heart attacks, strokes, and cardiovascular-related deaths).

Clinical Study Identifier: s22-00135 Identifier: NCT05030428

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.